The Mechanism and Efficacy of Baricitinib as a Novel Therapeutic option for Rheumatoid Arthritis: A Review

Abstract

Rheumatoid arthritis (RA) is characterized by systemic synovitis, which destroys joints. With the discovery of biological disease-modifying anti-rheumatic medicines (bDMARDs) and the combination of traditional DMARDs, clinical remission is now seen as a reasonable and achievable aim for many patients. However, bDMARDs must be administered via intravenous or subcutaneous injection, and some patients may not react or lose their main response. Under these conditions, targeted synthetic DMARDs (tsDMARDs), which are low. molecular-weight molecules that may be taken orally, have emerged. Five phase 3 studies of Baricitinib, a JAK1(janus kinase1) and JAK2(janus kinase 2) inhibitor, demonstrated good clinical effectiveness in patients with active RA who were naïve to sDMARDs or had an unsatisfactory response to sDMARDs, MTX(methotrexate) or bDMARDs. In patients with rheumatoid arthritis who had not previously been treated with biologic disease-modifying Antirheumatic medications (DMARDs), Baricitinib, an oral inhibitor of Janus kinase 1 and 2, decreased disease activity.